Our lab is focused on developing novel therapeutic strategies that target leukemia and leukemia stem cells. Using chemical and genetic approaches, our laboratory investigates targeting protein synthesis and degradation pathways in the mitochondria and cytoplasm. Mechanistic studies are coupled with preclinical evaluation to understand the biology of leukemia stem cells and highlight therapeutic strategies with potential therapeutic windows. In addition to acting as biological tools, these molecules also serve as leads for potential new treatment strategies. For example, using these approaches, we have demonstrated that acute myeloid leukemia (AML) cells and stem cells have a unique reliance on mitochondrial metabolism and have heightened sensitivity to inhibitors of mitochondrial translation. We have also demonstrated increased lysosomal mass in AML cells and increased sensitivity to lysosome disruption in this disease. To rapidly identify and test new therapeutic strategies in early proof-of-principle clinical trials, the Schimmer lab has also advanced compounds directly from the lab into Phase I clinical trials.
Aaron D Schimmer
Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy.
Blood Adv. 2017 Sep 12;1(20):1729-1738
Effect of an Antimicrobial Stewardship Programme on Antimicrobial Utilisation and Costs in Patients with Leukaemia: A Retrospective Interventional Controlled Study.
Clin Microbiol Infect. 2017 Nov 11;:
Aspergillus galactomannan detection in exhaled breath condensate compared to bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in immunocompromised patients.
Clin Microbiol Infect. 2017 Sep 29;:
JCI Insight. 2017 Sep 21;2(18):
Leuk Res. 2017 Aug 25;61:39-43
Distribution and Impact of Comorbidities on Survival and Leukemic Transformation in Myeloproliferative Neoplasm-Associated Myelofibrosis: A Retrospective Cohort Study.
Clin Lymphoma Myeloma Leuk. 2017 Jun 29;:
Cancer Discov. 2017 Jul;7(7):670-672
Psychooncology. 2017 Jun 30;:
Sharing post-AML consolidation supportive therapy with local centers reduces patient travel burden without compromising outcomes.
Leuk Res. 2017 Jun 01;59:93-96
Senior Scientist, Princess Margaret Cancer Centre
Professor, Department of Medical Biophysics, University of Toronto
Staff Physician, Leukemia Site Group, Princess Margaret Cancer Centre